title: Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible.
abstract: Lung cancer is the leading cause of cancer death in the United States with a five-year survival of 16.8% for all stages and median survival of four months for Stage IV disease. We report a case of a 54-year-old male with a seven-year survival after being diagnosed with Stage IV epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative adenocarcinoma of the lung, demonstrating an exceptional response to treatment.
authors.affiliation: Department of Hematology and Oncology, Staten Island University Hospital.
authors.forename: Shiksha
authors.initials: S
authors.lastname: Kedia
authors.affiliation: Department of Hematology and Oncology, Staten Island University Hospital.
authors.forename: Gwenalyn
authors.initials: G
authors.lastname: Garcia
authors.affiliation: Department of Hematology and Oncology, Staten Island University Hospital.
authors.forename: Meekoo
authors.initials: M
authors.lastname: Dhar
keywords: long-term survival; lung cancer; stage iv lung cancer
references.citation: J Clin Oncol. 2010 Feb 1;28(4):614-9
references.pmid: 19841321
references.citation: Lung Cancer. 2010 Sep;69(3):315-8
references.pmid: 20071052
references.citation: Indian J Med Paediatr Oncol. 2013 Apr;34(2):121-5
references.pmid: 24049303
references.citation: CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
references.pmid: 25559415
references.citation: J Thorac Oncol. 2007 Aug;2(8):686-93
references.pmid: 17762334
references.citation: J Clin Oncol. 1986 May;4(5):702-9
references.pmid: 3701389
references.citation: Lancet Oncol. 2010 Jun;11(6):521-9
references.pmid: 20493771